We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBsf Enterprise. Regulatory News (BSFA)

Share Price Information for Bsf Enterprise. (BSFA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.75
Bid: 4.50
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.50 (11.111%)
Open: 4.75
High: 4.75
Low: 4.75
Prev. Close: 4.75
BSFA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Prospectus & Notice of GM

7 Sep 2023 09:46

RNS Number : 7218L
BSF Enterprise PLC
07 September 2023
 

RNS Number: 5566J

BSF Enterprise PLC7 September 2023

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN ANY JURISDICTION.

 

7 September 2023

BSF Enterprise PLC

Publication of Prospectus

Notice of General Meeting

BSF Enterprise Plc (LSE: BSFA) (OTCQB: BSFAF) (the "Company"), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that, further to the conditional fundraising announced on 29 March 2023, 12 April 2023 and 14 April 2023 ("Previous Announcements"), the Company has today received approval from the Financial Conduct Authority (the "FCA") of its prospectus (the "Prospectus") relating to the proposed issuance (the "Share Issue") of up to 29,542,200 new ordinary shares ("Ordinary Shares") and has published its Prospectus.

 

The Share Issue relates primarily to the future warrants (Placing Warrants, Subscription Warrants and Broker Warrants at a price of 34 pence per share) that were part of the £2.9 million fundraise in March this year.

 

As described in the Previous Announcements, the Company raised approximately £2.9 million by way of Fundraising, comprising the Placing of 16,317,648 Placing Shares and the Subscription of 882,352 Subscription Shares at a price of 17 pence per share.

 

The Subscription was structured in two tranches. The first tranche consisting of 617,613 Ordinary Shares were allotted and issued pursuant to the then Company's existing authorities, in addition to the Placing Shares, and were admitted to the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange on 14 April 2023.

 

The second tranche of Subscription consisting of 264,739 Ordinary Shares, together with the 100,000 Financial PR Shares to be issued to Roast PR in satisfaction of certain fees due for services rendered at a price of 17 pence per share, will be allotted and issued subject to the passing of resolutions at the general meeting.

A notice of general meeting (the "Notice of GM") is being posted today to shareholders where the Board recommends shareholders to vote in favour of the resolutions. The Company will convene the general meeting at 10:00 a.m. on 26 September 2023 at the offices of Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW, to consider and approve, among other matters, the allotment of shares and disapplication of pre-emption rights in relation to the Share Issue.

 

An electronic copy of the Prospectus and Notice of GM are available for inspection on the Company's website at www.bsfenterprise.com. The Prospectus will also be available for inspection at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

It is expected that admission of the new Ordinary Shares will become effective at or around 8.00 a.m. on 27 September 2023 and that dealings in the new Ordinary Shares will commence at that time. The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company and will on issue be free of all claims, liens, charges, encumbrances and equities.

Further announcements will be made in due course, as appropriate.

Terms used in this announcement shall, unless the context otherwise requires, be as dened in the Prospectus published by the Company on 7 September 2023 in relation to the Share Issue.

For further enquiries, please visit www.bsfenterprise.com or contact:

 

 

BSF Enterprise PLC

 

 

Via SEC Newgate below

Geoff Baker - Executive Director

Che Connon - CEO & Director

 

Shard Capital (Broker)

Damon Heath

Isabella Pierre

020 7186 9900

0207 186 9927

 

SEC Newgate (Financial Communications)

Bob Huxford

Elisabeth Cowell

George Esmond

020 3757 6882

BSF@secnewgate.co.uk

 

ISIN of the Ordinary Shares is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAPNXELADEEA
12
Date   Source Headline
11th Apr 20247:00 amRNSSuccessful Cultivated Leather PoC Agreements
20th Mar 202412:56 pmRNSResult of Annual General Meeting
20th Mar 202410:19 amRNSUniversity Collaborations
14th Mar 20247:00 amRNSInvestor Evening
7th Mar 20247:00 amRNSBSF Enterprise and Ivy Farm Enter Partnership
29th Feb 20247:00 amRNSMoU with Sustainable Fashion Company
26th Feb 20247:27 amRNSNotice of AGM
22nd Feb 20247:00 amRNSKerato Limited - Update
15th Feb 20247:00 amRNSStrategic Update
31st Jan 20247:00 amRNSFull Year Results
8th Dec 20237:00 amRNSFOODTECH Joint Venture with CellRev
30th Nov 20233:07 pmRNSStandard form for notification of major holdings
24th Nov 20237:00 amRNS3D Bio-Tissues Product Partnership Progress
26th Oct 20237:00 amRNSNew Cornea Company & Investor Update
9th Oct 20239:34 amRNSParticipation in The ThinkEquity Conference
26th Sep 20232:32 pmRNSResults of General Meeting & Allotment of Shares
18th Sep 20237:00 amRNS3D Bio-Tissues receives EUR612,000 grant
11th Sep 20237:00 amRNSStrategic Update
7th Sep 20239:46 amRNSPublication of Prospectus & Notice of GM
17th Jul 20237:00 amRNSCity-Mix Bio-Pharmaceutical Update
3rd Jul 20239:56 amRNSOpens Office in Hong Kong
29th Jun 20237:00 amRNSInterim Results
23rd Jun 202311:30 amRNSCultivated Meat Approved for Consumption in US
8th Jun 20237:00 amRNSUS Investor Roadshow & Appointment of US IR Agency
1st Jun 20237:00 amRNSPublication of New Research
30th May 20237:00 amRNSSuccessful Cultivated Meat Test
25th May 20237:00 amRNSAdmittance to trading on the OTCQB Venture Market
22nd May 20237:00 amRNSCommercial Progress Update
15th May 20237:00 amRNSLab-Grown Leather Update and Innovation Award Win
21st Apr 20237:00 amRNSShowcase Meat Update
14th Apr 20238:00 amRNSAdmission of Placing Shares & Subscription Shares
12th Apr 20233:35 pmRNSUpdate to Oversubscribed £2.9 million fundraise
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 20237:00 amRNSOversubscribed £2.9 million fundraise
15th Mar 202311:59 amRNSResult of Annual General Meeting
15th Mar 20237:00 amRNSAGM Statement
9th Mar 20238:53 amRNSApplication for Trading on US OTCQB Venture Market
6th Mar 20237:00 amRNSCity-Mix Commercial Progress Update
20th Feb 20233:00 pmRNSNotice of AGM
10th Feb 20237:00 amRNSAllotment of shares
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20232:05 pmRNSSecond Price Monitoring Extn
1st Feb 20232:00 pmRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSUK’s First Fillet of Cultivated Meat Produced
31st Jan 20234:36 pmRNSAnnual Report and Financial Statements
19th Dec 20227:00 amRNS3D Bio-Tissues enters partnership with New Harvest
23rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20227:00 amRNS3D Bio-Tissues partners with cell growth company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.